Cargando…

Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciuoderis, Karl, Perez, Laura, Alvarez, Catalina, Usuga, Jaime, Carvajal, Leidi, Cardona, Andrés, Maya, Maria A., Cloherty, Gavin, Hernandez-Ortiz, Juan P., Osorio, Jorge E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156422/ https://www.ncbi.nlm.nih.gov/pubmed/37138300 http://dx.doi.org/10.1186/s13256-023-03904-2

Ejemplares similares

Assessment of SARS-CoV-2 Mu Variant Emergence and Spread in Colombia
por: Hernandez-Ortiz, Juan, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

The Principles of SARS-CoV-2 Intervariant Competition Are Exemplified in the Pre-Omicron Era of the Colombian Epidemic
por: Orf, Gregory S., et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Oropouche virus as an emerging cause of acute febrile illness in Colombia
por: Ciuoderis, Karl A., et al.
Publicado: (2022)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
por: Kuzel, Timothy G, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

SARS‐CoV‐2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID‐19 due to Omicron BA.1 and BA.2
por: de Michelena, Paula, et al.
Publicado: (2022)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Omicron breakthrough infections in vaccinated or previously infected hamsters
por: Zhou, Jie, et al.
Publicado: (2023)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
por: Marking, Ulrika, et al.
Publicado: (2023)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone
por: da Silva, Eveline Santos, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
por: Quandt, Jasmin, et al.
Publicado: (2022)

Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays
por: Boler, Michael, et al.
Publicado: (2023)

Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
por: Platen, Louise, et al.
Publicado: (2023)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
por: Wei, Jia, et al.
Publicado: (2023)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
por: Nutalai, Rungtiwa, et al.
Publicado: (2022)

Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
por: Seaman, Michael S., et al.
Publicado: (2022)

Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection
por: Planas, Delphine, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Urticaria física /
por: Hernández Osorio, Francisco Javier
Publicado: (1987)

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection
por: Rose, Ruben, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lknfil91e34ph4muujmhtbamul